Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2019³â Á¦35Â÷ Workshop °³ÃÖ ¾È³»
"Connecting the Dots in Drug Discovery"
2019³â 5¿ù 23ÀÏ(¸ñ) 09:00~17:40 / °æ±â°æÁ¦°úÇÐÁøÈï¿ø °æ±âȦ
1. ±Í»çÀÇ ¹«±ÃÇÑ ¹ßÀü°ú ±ÍÇÏÀÇ °Ç½ÂÇϽÉÀ» ±â¿øÇÕ´Ï´Ù.
2. Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸¿¡¼´Â Á¦35Â÷ ¿öÅ©¼¥À» "Connecting the Dots in Drug Discovery" À̶ó´Â ÁÖÁ¦·Î ´ÙÀ½°ú °°ÀÌ °³ÃÖÇÏ¿À´Ï, ȸ¿ø ¿©·¯ºÐÀÇ ¸¹Àº Âü¿© ¹Ù¶ø´Ï´Ù.
3. ÃÑȸ¿¡¼ Á¤°ü °³Á¤¿¡ ´ëÇÑ ½ÉÀÇ ¹× ÀǰáÀÌ ÀÖÀ» ¿¹Á¤ÀÌ¿À´Ï ȸ¿øºÐµéÀº ¸ðµÎ Âü¼®ÇØÁֽñ⠹ٶø´Ï´Ù.
|
¡á Çà»ç°³¿ä
Çà»ç¸í |
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2019³â Á¦35Â÷ Workshop |
ÁÖÁ¦ |
Connecting the Dots in Drug Discovery |
ÀϽà |
2019³â 5¿ù 23ÀÏ(¸ñ) 09:00~17:40 |
Àå¼Ò |
°æ±â°æÁ¦°úÇÐÁøÈï¿ø °æ±âȦ (±¸, °æ±âÁß¼Ò±â¾÷Áö¿ø¼¾ÅÍ) ÀÚ¼¼È÷ º¸±â
ÁÖ¼Ò : °æ±âµµ ¼ö¿ø½Ã ¿µÅ뱸 ±¤±³·Î 107
|
»çÀüµî·Ï±â°£ |
2019³â 4¿ù 10ÀÏ (¼ö) ~ 5¿ù 17ÀÏ (±Ý)
1) ȨÆäÀÌÁö (www.nonclinical.or.kr)³» Á¦35Â÷ ¿öÅ©¼¥ »çÀüµî·Ï ¸Þ´º ÀÌ¿ë
2) ºñȸ¿øÀº ȸ¿ø°¡ÀÔ ÈÄ µî·Ï °¡´É
|
µî·Ïºñ |
»çÀüµî·Ï 5¸¸¿ø(Çлý 2¸¸¿ø), ÇöÀåµî·Ï 7¸¸¿ø(Çлý 4¸¸¿ø)
1) »çÀüµî·Ï Ä«µå°áÁ¦ °¡´É.(Ä«µå°áÁ¦ ½Ã ¼¼±Ý°è»ê¼ ¹ßÇàºÒ°¡)
2) ÀÚ·áÁý, ¼ö·áÁõ, Áᫎ Æ÷ÇÔ
3) ¼¼±Ý°è»ê¼ ¹ß±Þ (ÀÔ±ÝÀÏ ±âÁØ 1ȸ ¹ß±Þ)ÀÌ ÇÊ¿äÇϽŠºÐÀº »ç¾÷ÀÚµî·ÏÁõ ÷ºÎ ¿ä¸Á
4) ÇöÀåµî·ÏÀÇ °æ¿ì, ¼¼±Ý°è»ê¼ ¹ß±Þ ºÒ°¡, ¿¬±¸È¸ ÀÚü ¿µ¼öÁõ ¹ß±Þ
5) ÀԱݰèÁÂ: ¿ì¸®ÀºÇà 1005-403-436526 ¢ßµå¸²ÆÄÆ®³Ê Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸
6) ÀԱݸ¶°¨: 2019³â 5¿ù 17ÀÏ(±Ý), ÀÔ±Ý ½Ã ¼Ò¼Ó, ¼º¸í ±âÀÔ ¿ä¸Á |
°ü·Ã°ø¹®
|
°ø¹® - Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2019 Á¦35Â÷ Workshop °³ÃÖ ¾È³»
¸®Ç÷¿ - Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ 2019 Á¦35Â÷ Workshop °³ÃÖ ¾È³»
|
¹®ÀÇ |
±âŸ ¹®ÀÇ»çÇ×Àº Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ »ç¹«±¹À¸·Î ¹®ÀÇÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
KSNS »ç¹«±¹ : Tel. 031-702-9123 / E-mail. ksns@nonclinical.or.kr / ´ã´çÀÚ. ±èÁذï
|
¡á µî·Ï¾È³»
- »çÀüµî·Ï ¾È³»
µî·Ï±â°£ |
2019³â 4¿ù 10ÀÏ (¼ö) ~ 5¿ù 17ÀÏ (±Ý) |
µî·Ï¹æ¹ý |
- ¿¬±¸È¸ ȨÆäÀÌÁö (www.nonclinical.or.kr) ÇмúÇà»ç >»çÀüµî·Ï ¸Þ´º ÀÌ¿ë
- ºñȸ¿øÀº ȸ¿ø°¡ÀÔ ÈÄ, »çÀüµî·ÏÀÌ °¡´ÉÇÕ´Ï´Ù.
|
- µî·Ïºñ <Áß¿ä°øÁö >Ä«µå°áÁ¦ °¡´É
µî·Ïºñ ±¸ºÐ |
»çÀüµî·Ï |
ÇöÀåµî·Ï |
Á¤È¸¿ø |
50,000¿ø |
70,000¿ø |
Çлýȸ¿ø |
20,000¿ø |
40,000¿ø |
• »çÀüµî·Ïºñ : ÀÚ·áÁý, ¼ö·áÁõ, Áᫎ Æ÷ÇÔ
• ¼¼±Ý°è»ê¼ ¹ß±Þ(ÀÔ±ÝÀÏ ±âÁØ 1ȸ ¹ß±Þ)ÀÌ ÇÊ¿äÇÒ °æ¿ì, ¿Â¶óÀÎ µî·Ï ½Ã ¼¼±Ý°è»ê¼ ¹ßÇà¿©ºÎ¸¦ üũÇϰí, »ç¾÷ÀÚµî·ÏÁõ »çº»À» ¹Ýµå½Ã ÷ºÎ
• ÇöÀåµî·Ï ¹× Çлýµî·ÏÀÇ °æ¿ì, ¼¼±Ý°è»ê¼ ¹ß±Þ ºÒ°¡, ¿¬±¸È¸ ÀÚü ¿µ¼öÁõ ¹ß±Þ |
- ¹«ÅëÀåÀÔ±Ý (°èÁÂÀÌü)
ÀԱݰèÁ |
¿ì¸®ÀºÇà 1005-403-436526 ¢ßµå¸²ÆÄÆ®³Ê Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ |
ÀԱݰèÁ |
~ 2019³â 5¿ù 17ÀÏ (±Ý) 18½Ã ±îÁö |
• ÀԱݽà ¹Ýµå½Ã "¼Ò¼Ó/¼º¸í" À» ±âÀÔÇϼ¼¿ä.
• ¹«ÅëÀå ÀÔ±Ý(°èÁÂÀÌü)ÀÌü ÈÄ, »ç¹«±¹¿¡¼ ÀÔ±ÝÀ» È®ÀÎÇÏ´Â ½Ã°£ÀÌ ÇÊ¿ä ÇÕ´Ï´Ù.
• ±âŸ µî·Ï °ü·Ã ¹®ÀÇ»çÇ×Àº Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ »ç¹«±¹À¸·Î ¹®ÀÇÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
TEL. 031-702-9123 / E-mail. ksns@nonclinical.or.kr, ±èÁذï
|
¡á ÇÁ·Î±×·¥ ¾È³»
- ÀϽà : 2019³â 5¿ù 23ÀÏ(¸ñ) 09:00~17:40
- Àå¼Ò : °æ±â°æÁ¦°úÇÐÁøÈï¿ø °æ±âȦ(°æ±âµµ ¼ö¿ø½Ã ¿µÅ뱸 ±¤±³·Î 107)
- ÁÖÁ¦ : Connecting the Dots in Drug Discovery
|
½Ã°£ |
ÇÁ·Î±×·¥ |
09:00~09:40 |
µî·Ï |
09:40~09:50 |
°³ ȸ »ç (ȸÀå, ¿À¼¼¿õ) |
09:50~10:00 |
Ãà»ç (´ëÇѾàÇÐȸÀå, À̿뺹) |
Session 1 |
Plenary |
10:00~10:40 |
4Â÷ »ê¾÷Çõ¸í°ú Á¦¾à¡¤¹ÙÀÌ¿À ±â¼ú¸¶ÄÉÆÃ ÇöȲ°ú Àü·«
(4th Industrial Revolution and Current Status and Strategy of Pharma-Bioceutical Licensing) |
Á¶ÇåÁ¦
Çѱ¹½Å¾à°³¹ß¿¬±¸Á¶ÇÕ |
Session 2 |
Platform |
10:40~11:20 |
Novel Hit Discovery using DNA Encoded Library Technology |
DengFeng Dou
HITGEN |
11:20~12:00 |
Development of Innovative Therapeutics Using BioDrone Platform Based on Cell-Derived Vesicles |
¹è½Å±Ô
¿¥µð¹Ã |
12:00~13:30 |
Luncheon Symposium & Booth Exhibition |
Session 3-1 |
µ¶¼ººÐ°ú |
13:30~14:10 |
How To Survive Critical Adverse Data |
Christopher Stewart
SGI Consulting, LLC. |
14:10~14:50 |
Safety of the Stem Cell Therapy |
Á¶½ÂÁÖ
KBIOHEALTH |
14:50~15:30 |
Developing CARs-based T Cell Adoptive Immunotherapy |
Enrico Pesenti
Accelera srl |
Session 3-2 |
¾àµ¿ºÐ°ú |
13:30~14:10 |
»ý¹°ÀǾàǰ °³¹ß ½Ã °í·ÁÇØ¾ß ÇÒ ¾àµ¿ÇÐÀû Ư¼º
(Pharmacokinetic Properties to Consider for Developing Biologics) |
À±ÈÖ¿
Ãæ³²´ë |
14:10~14:50 |
ÀÓ»ó °³¹ß Áß ºñÀÓ»ó °á°ú¸¦ °í·ÁÇÑ ÀÇ»ç °áÁ¤
(Decision Marking Considering Non-Clinical Results for Clinial Development) |
ÇѽÂÈÆ
¼¿ï¼º¸ðº´¿ø |
14:50~15:30 |
Translational models of obesity, dysmetabolism, diabetes & complications: Nephropathy, NASH, Cardiomyopathy |
Jim Wang
Crown Bioscience Inc |
Session 3-3 |
¾àÈ¿ºÐ°ú / °Ç±¹´ë ¹ÙÀÌ¿ÀÀ̹Ì¡¼¾ÅÍ °øµ¿½ÉÆ÷Áö¿ò |
13:30~14:10 |
½Ç½Ã°£ ¹ß±¤¿µ»ó±â¼úÀ» ÀÌ¿ëÇÑ Ç׿ì¿ïÁ¦ÀÇ ºÐÀÚ»ý¹°ÇÐÀû ±âÀÛ ±Ô¸í
(Identification of Molecular Mechanisms of Antidepressants Using Bio-Optical Imaging Technology) |
Çã¼Û¿í
±âÃʰúÇÐÁö¿ø¿¬±¸¿ø |
14:10~14:50 |
Multi-parametric MRI ½Å¾à°³¹ß ÀÀ¿ë
(Application of Multi-Parametric MRI for New Drug R&D) |
ÀÌÀçÁØ
¿À¼Û÷´ÜÀÇ·á»ê¾÷ÁøÈï¿ø |
14:50~15:30 |
½Å¾à°³¹ß ÀüÀÓ»ó¿¡¼ ¹æ»ç¼º µ¿À§¿ø¼Ò¸¦ Ȱ¿ëÇÑ »ýü ºÐÀÚ¿µ»ó
(Biomolecular Imaging Using Radioactive Isotopes in Pre-Clinical Development of New Drugs) |
ÃÖÀç¿ë
¿øÀÚ·ÂÀÇÇבּ¸¿ø |
Session 4 |
Case study |
16:00~16:40 |
CKD-506 in autoimmune diseases (non-clinical studies) |
½ÅÁöÀº
Á¾±Ù´ç |
16:40~17:20 |
Strategies for Biosimilar Development; RemsimaTM |
ÀüȲ±Ù
¼¿Æ®¸®¿Â |
17:20~17:30 |
ÃÑȸ |
17:30~17:50 |
Æó ȸ »ç ¹× °æÇ° Ãß÷ (ºÎȸÀå, ½ÉÇöÁÖ) |
18:00 ~ |
°£ Ä£ ȸ (Àå¼Ò º°µµ °øÁö) |
* »ó±â ÇÁ·Î±×·¥Àº ¿¬ÀÚ ¹× ±âŸ »çÁ¤À¸·Î º¯µ¿ ¼ö ÀÖ½À´Ï´Ù.
¡á ¿À½Ã´Â ±æ
ÁÖ¼Ò |
°æ±âµµ ¼ö¿ø½Ã ¿µÅ뱸 ±¤±³·Î 107 (Áö¹ø: °æ±âµµ ¼ö¿ø½Ã ¿µÅ뱸 ÀÌÀǵ¿ 906-5) |
ȨÆäÀÌÁö |
°æ±â°æÁ¦°úÇÐÁøÈï¿ø °æ±âȦ (±¸, °æ±âÁß¼Ò±â¾÷Áö¿ø¼¾ÅÍ) ÀÚ¼¼È÷ º¸±â
|
|
ÁöÇÏö·Î ¿À½Ã´Â °æ¿ì
- ÁöÇÏöÀ» ÀÌ¿ëÇÏ¿© ±¤±³Áß¾Ó¿ª(½ÅºÐ´ç¼±)¿¡¼ ¿À½Ã´Â °æ¿ì
(µµº¸) 3¹ø Ãⱸ¿¡¼ Ⱦ´Üº¸µµ »ï°Å¸®±îÁö À̵¿ÇÏ¿© Ⱦ´Üº¸µµ¸¦ °Ç³Í ÈÄ, ¿ùµåÄŰæ±âÀå ¹æ¸éÀ¸·Î ¾à 500m µµº¸ (¾à 20ºÐ ¼Ò¿ä) (´ëÁß±³Åë) 3¹ø Ãⱸ¿¡¼ ¾à 300m µµº¸ À̵¿ÇÏ¿© ±¤±³Áß¾Ó¿ª, ±¤±³°íµîÇб³ Á¤·ùÀå¿¡¼ 88-1¹ø ¶Ç´Â 13-4¹ø ž½Â ÈÄ °æÁ¦°úÇÐÁøÈï¿ø, °æ±âÀÏÀÚ¸®¼¾ÅÍ Á¤·ùÀå ÇÏÂ÷ (¾à 20ºÐ ¼Ò¿ä)
- ÁöÇÏöÀ» ÀÌ¿ëÇÏ¿© ¼ö¿ø¿ª(1È£¼±)¿¡¼ ¿À½Ã´Â °æ¿ì
9¹øÃⱸ ¸Å»ê½ÃÀå Á¤·ùÀå¿¡¼ ½ÂÂ÷ (7, 9-2, 13-4, 7202¹ø) °æÁ¦°úÇÐÁøÈï¿ø, °æ±âÀÏÀÚ¸®¼¾ÅÍ Á¤·ùÀå¿¡¼ ÇÏÂ÷ ÈÄ È¾´Üº¸µµ ¸ÂÀºÆí Á÷Áø 300m µµº¸
- ÁöÇÏöÀ» ÀÌ¿ëÇÏ¿© ¼ö¿ø½Ãû¿ª(ºÐ´ç¼±)¿¡¼ ¿À½Ã´Â °æ¿ì
9¹øÃⱸ ±¹¹Î¿¬±Ý°ø´Ü Á¤·ùÀå¿¡¼ ½ÂÂ÷ (85¹ø) °æÁ¦°úÇÐÁøÈï¿ø, °æ±âÀÏÀÚ¸®¼¾ÅÍ Á¤·ùÀå¿¡¼ ÇÏÂ÷ ÈÄ È¾´Üº¸µµ ¸ÂÀºÆí Á÷Áø 300m µµº¸
|
|